Recently, the Task Force (TF) of the National Psoriasis Foundation (NPF) released a revised version of its COVID-19 statement after an in-depth analysis of publicly available data with two currently approved anti-SARS-CoV-2 vaccines in the US, both mRNA-based.

While the news of a potential SARS-CoV-2 vaccine is to be welcomed, the impact of psoriasis therapy, particularly systemic therapy, on the effectiveness and safety of vaccines needs to be considered.

Commentary provided on this international moderate-severe psoriasis case series, where biologics use was associated with lower risk of COVID-19-related hospitalization than non-biologic systemic therapies, however further investigation is warranted due to potential selection bias and unmeasured confounding.

According to a new paper published by the team behind the PsoProtect registry, psoriasis patients treated with biologics are at a lower risk of being hospitalized due to COVID-19 than those treated with non-biologic systemic therapies.

PsoProtect, the global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis, has updated their preliminary data so that it now includes the first 200 cases.

IPC Founding President Alan Menter and IPC Councilor Ulrich Mrowietz discuss the new guidance on psoriasis care from the National Psoriasis Foundation COVID-19 Task Force.

Declaración del IPC sobre COVID y psoriasis La pandemia de SARS-CoV-2 continúa siendo una preocupación sanitaria de gravedad a nivel global. Desde que el Consejo Internacional de Psoriasis (IPC) publicó su declaración sobre COVID-19 el 11 de marzo, el coronavirus continúa propagándose rápidamente y actualmente constituye un peligro sanitario preponderante en todos los países de ingresos económicos altos, medios y bajos.

IPC fellow Dr. Romina Contreras talks with Dr. Alba Català about her study on skin manifestations of COVID-19 and how this research contributes to our growing understanding of the novel coronavirus.

Ricardo Romiti, MD, PhD, discusses the COVID-19 situation in Brazil from a derm perspective.

The registries, PsoProtect and PsoProtectMe, aim to help health care workers understand how the novel virus affects patients with psoriasis.